; (2) aplastic anemia; (3) paroxysmal nocturnal hemoglobinuria (PNH); (4) pure red cell aplasia; (5) acute myeloid leukemia that progressed from myelodysplastic syndromes; or (6) large granular lymphocytic leukemia. D Cardiovascular Disease, Chronic Disease, and Other Disease Issues 731. Guidelines for disease screening for minority patients (a) In general The Secretary, acting through the Director of the Agency for Healthcare Research and Quality, shall convene a series of meetings to develop guidelines for disease screening for minority patient populations which have a higher than average risk for many chronic diseases and cancers. (b) Participants In convening meetings under subsection (a), the Secretary shall ensure that meeting participants include representatives of— (1) professional societies and associations; (2) minority health organizations; (3) health care researchers and providers, including those with expertise in minority health; (4) Federal health agencies, including the Office of Minority Health, the National Institute on Minority Health and Health Disparities, and the National Institutes of Health; and (5) other experts determined appropriate by the Secretary. (c) Diseases Screening guidelines for minority populations shall be developed as appropriate under subsection (a) for— (1) hypertension; (2) hypercholesterolemia; (3) diabetes; (4) cardiovascular disease; (5) cancers, including breast, prostate, colon, cervical, and lung cancer; (6) other pulmonary problems including sleep apnea; (7) asthma; (8) diabetes; (9) kidney diseases; (10) eye diseases and disorders, including glaucoma; (11) HIV/AIDS and sexually transmitted infections; (12) uterine fibroids; (13) autoimmune disease; (14) mental health conditions; (15) dental health conditions and oral diseases, including oral cancer; (16) environmental and related health illnesses and conditions; (17) sickle cell disease and sickle cell trait; (18) violence and injury prevention and control; (19) genetic and related conditions